美诺华：控股子公司阿托伐他汀钙原料药通过CDE技术审评

Core Viewpoint - Meinuo Pharma (603538.SH) has received approval from the National Medical Products Administration for its atorvastatin calcium raw material drug, which will enhance its product line and expand its business scope [1] Group 1: Regulatory Approval - The company’s subsidiary, Xuancheng Meinuo, received the approval notice for atorvastatin calcium raw material drug with registration number Y20240000440 [1] - The application for the drug was submitted to the CDE on May 16, 2024, and it passed the review on December 17, 2025, with a registration status marked as "A" [1] Group 2: Financial Investment - The total R&D investment for the atorvastatin calcium raw material drug amounted to 14.9496 million yuan (approximately 2.1 million USD) [1] Group 3: Business Expansion - The approval of atorvastatin calcium raw material drug will enrich the subsidiary's product line and help expand the company's business areas [1] - This development is expected to enhance the company's integrated production advantages in the raw material drug formulation sector [1]